The US Food & Drug Administration is preparing for a significant workload increase toward year-end as cell and gene therapy sponsors attempt to salvage or restart clinical trials affected by the COVID-19 pandemic – just as the work on the novel coronavirus starts to subside.
“In the latter part of this year, as the COVID response starts to dissipate and wind down, I’m concerned that...








